CRNX vs PRAX
CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors. PRAX: Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing precision therapies for central nervous system disorders driven by neuronal imbalance.
Side-by-side fundamentals
| Metric | CRNX | PRAX | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $84.08 | $360.76 | |
| Market cap as of 2026-08-10 | $8.9B | $10.1B | |
| PEG as of 2026-08-10 | -0.73 | -5.38 | PRAX lower |
| Net margin as of 2026-08-10 | -1189.9% | -2137.5% | CRNX higher |
| Gross margin as of 2026-08-10 | +86.0% | n/a | |
| Operating margin as of 2026-08-10 | -1302.5% | -2340.3% | CRNX higher |
| ROE as of 2026-08-10 | -44.2% | -43.0% | PRAX higher |
| ROA as of 2026-08-10 | -39.8% | -40.2% | CRNX higher |
| Debt / equity as of 2026-08-10 | 0.00 | 0.00 | Tie |
| Beta as of 2026-08-10 | 0.02 | 2.82 | |
| 1-year return as of 2026-08-07 close | +201.6% | +663.2% | PRAX higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.